论文部分内容阅读
基于CD3抗原广泛存在于成熟T细胞表面的理论基础,我们应用CD3单克隆抗体与IL-2在体外成功诱导出了具有较好增殖活性的CD3抗体激活的杀伤细胞(CD3AK细胞),并对其抗喉癌作用进行了观察和研究.结果表明:与常规培养的LAK细胞相比,以健康人新鲜外周静脉血单个核细胞为前体、经CD3单抗(4μg/ml)和IL-2(1000U/ml)诱导产生的CD3AK细胞具有集落形成率高、体外扩增能力强、存活时间长、抗瘤作用持久稳定等优势.在培养初期,CD3AK细胞的扩增情况与LAK细胞相似,但CD3AK细胞生长后劲明显,于培养8～10天达增殖高峰,平均扩增18.5倍,并可维持体外长期存活达两周之久,而同期培养的LAK细胞1周时平均仅增5.5倍,且多于1周后逐渐死亡,二者相比有非常显著性差异;同时,CD3AK细胞在体
Based on the rationale that CD3 antigen exists on the surface of mature T cells, we successfully induced CD3 antibody-activated killer cells (CD3AK cells) with CD3 mAb and IL-2 in vitro, Anti-laryngeal cancer effect was observed and studied. The results showed that compared with routine cultured LAK cells, healthy peripheral blood mononuclear cells were used as precursors and CD3 monoclonal antibody (4μg / ml) and IL-2 1000U / ml) induced CD3AK cells have the advantages of high rate of colony formation, strong ability of expansion in vitro, long survival time and long-term anti-tumor effect.In the early stage of culture, the expansion of CD3AK cells is similar to that of LAK cells, but CD3AK Cell growth stamina significantly, in the cultivation of 8 to 10 days peak in proliferation, an average of 18.5 times amplification, and can maintain long-term survival in vitro for two weeks, while the same period of LAK cells cultured an average of only 5.5 times a week, and more than 1 Gradually died after weeks, both compared to a very significant difference; the same time, CD3AK cells in vivo